Actualités

Under the agreement, Johnson & Johnson would make total initial payments of $785 million, and has the exclusive option to acquire Sail for $2.58 billion.

But is that performance sustainable?

Moby summary of Anika Therapeutics, Inc.'s Q2 2026 earnings call

Eighteen thousand dollars a month is the number a lot of high earners target for retirement: it replaces a $216,000 salary, covers property taxes in a coastal state, and funds the lifestyle most doctors, senior engineers, and business owners built around. On a $3 million portfolio, hitting that figure requires a blended yield of roughly ... This $3 Million Portfolio Pays $18,000 a Month From Three Income Buckets

The sticker shock on the pharma giant's shares fades once you look at what investors are paying for the earnings expected just two years from now.

GSK beats Q2 earnings and revenue estimates, reaffirms 2026 guidance and unveils a new cost-saving plan.

Boston Scientific (BSX) lowered its full-year guidance below Wall Street's estimates on Wednesday, c

Host Kenny Polcari, Robinhood CIO Stephanie Guild, and Payne Capital Management President Ryan Payne discuss why they believe the AI trade is still alive, and how investors can reduce spending risk by looking beyond hyperscalers and semiconductors.

In the world of robotic surgery, one company is both the undisputed leader and the most expensive name on the shelf, forcing investors to ask if operational brilliance is worth the high price of admission.

Johnson & Johnson's revenue has grown modestly while Eli Lilly's revenue has nearly doubled in two years, narrowing a once-wide gap.

July 29 () - GE HealthCare on Wednesday beat Wall Street estimates for second-quarter profit, helped by strong demand for its ‌diagnostic and imaging devices and refunds of tariffs imposed under U. Shares of the medical device maker rose 12% in premarket trading.

July 29 (Reuters) - GE HealthCare on Wednesday beat Wall Street estimates for second-quarter profit, helped by strong demand for its diagnostic and imaging devices and refunds of tariffs imposed ​

Kenvue has lagged the broader market over the past year, leaving analysts with a measured view on the stock.

Retiring at 60 with a five-figure monthly paycheck sounds like it requires decades of maxing every tax-advantaged account you own, but a taxable brokerage and the right yield strategy can tell a very different story for a 44-year-old with 16 years on the clock.

Abbott Laboratories, Taiwan Semiconductor, and Johnson & Johnson have all delivered strong earnings releases in the Q2 cycle, with each breaking records while also lifting their outlooks.

Generating $7,000 a month in retirement sounds like a math problem, but for Medicare-eligible investors it's also a tax trap where chasing a higher yield can quietly trigger surcharges that claw back the gains.

Johnson & Johnson stock's oncology engine and its steady guidance raises were on the record quarters before the price moved.

One of the market's strongest health care performers barely moves with the index you already own, and that gap is the whole point.

Coca-Cola and Boeing are surging together for the first time in years as investors abandon AI darlings, and the catalyst behind each stock tells a very different story about where the market is heading.

Johnson & Johnson stock has delivered a 77.7% total return over the past five years, yet the latest valuation work suggests the current share price may still sit below an intrinsic value estimate based on a Discounted Cash Flow (DCF) model. At the same time, the broader checks paint a less generous picture, so investors are weighing a strong track record against a low overall value score. Over five years, Johnson & Johnson has returned 77.7%, which keeps the stock firmly in focus for...

AbbVie heads into Q2 earnings with Skyrizi and Rinvoq driving growth as investors weigh Humira declines and the company's long-term outlook.

Johnson & Johnson says it will pay an estimated $5.5 billion to settle about 76,000 lawsuits alleging its baby powder and talc caused ovarian cancer.

DGRO markets itself as a sleepy dividend fund, but its rulebook quietly funnels money toward mega-cap tech, and the compounding math behind that combination may rewrite which ETF actually wins over the next decade.

Johnson & Johnson (NYSE:JNJ) has reached an agreement to resolve tens of thousands of lawsuits in the US alleging that its talc-based products, including its baby powder, caused ovarian cancer, with the company committing up to $5.5 billion to settle the remaining claims. The proposed...

Johnson & Johnson has set aside $5.5 billion to resolve tens of thousands of US lawsuits alleging that its talcum powder-based products caused ovarian cancer.

Biotech earnings take center stage as Viking, Biogen, Bristol Myers, Regeneron and AbbVie prepare to report Q2 2026 results.

The deal covers about 76,000 ovarian cancer claims and requires acceptance by at least 95% of claimants to take effect

Johnson & Johnson has agreed to pay $5.5 billion to tie up remaining lawsuits that claim its talc products caused ovarian cancer. The drugmaker, which has been fighting talc-related lawsuits for more than a decade, said that the settlement is conditioned on at least 95% of remaining claimants participating. A U.S. bankruptcy court judge denied a $9 billion settlement proposed by company subsidiary Red River Talc last year that would have been one of the biggest mass tort settlements in history.

Micron, Nvidia, and other AI stocks struggle as investors fret about rising costs and competition from China.

Johnson & Johnson (J&J) has agreed to pay an estimated $5.5bn (£4.1bn) to resolve tens of thousands of claims that its baby powder caused ovarian cancer.